BRAINSTORM CELL THERAPEUTICS INC.
BCLIOther · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$10.0M | −$11.7M | −$21.4M | −$24.8M | −$24.5M | −$31.7M |
| Net income | −$10.3M | −$11.6M | −$17.2M | −$24.3M | −$24.5M | −$31.8M |
| Total assets | $1.0M | $1.8M | $4.2M | $8.5M | $29.3M | $51.3M |
| Total liabilities | $11.0M | $9.6M | $9.1M | $11.5M | $9.9M | $15.8M |
| Equity | −$10.0M | −$7.8M | −$4.9M | −$3.0M | $19.3M | $35.5M |
| EPS (diluted) | $-1.11 | $-2.31 | $-6.00 | $-0.66 | $-0.68 | $-1.07 |
| Shares out. | 6.5M | 68.3M | 36.7M | 36.5M | 35.7M | 26.2M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- 103.2%
- Return on assets
- −1008.5%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 1077.0%
- Debt / equity
- —
- Book value / share
- $-1.53
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -890.88distress
- Accruals / assets
- −326.0%clean
- Piotroski F-Score
- 2/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 severe● 2 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Aug 14, 2009
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2009
- NT 10-Qmissed a reporting deadline ↗Nov 17, 2008
- NT 10-Kmissed a reporting deadline ↗Mar 31, 2008
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2007
- NT 10-Qmissed a reporting deadline ↗Aug 15, 2006
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Armistice Capital, LlcPassive (13G)May 15, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Lebovits ChaimOfficer — President & CEO | Feb 26, 2026 | Grant | 1.8M | $0.00 |
| Yablonka UriOfficer — EVP & Chief Business Officer | Feb 26, 2026 | Grant | 150,000 | $0.00 |
| Patlis AllaOfficer — See Remarks | Feb 26, 2026 | Grant | 100,000 | $0.00 |
| Frenkel Jacob ADirector | Feb 26, 2026 | Grant | 200,000 | $0.00 |
| Arbel IritDirector | Feb 26, 2026 | Grant | 120,000 | $0.00 |
| Dagher Ibrahim B.Officer — Chief Medical Officer | Jan 1, 2025 | Grant | 50,000 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 53,390 | 4.0 | +0.1% |
| Apr 30, 2026 | 53,310 | 2.4 | -19.1% |
| Apr 15, 2026 | 65,893 | 3.2 | -30.4% |
| Mar 31, 2026 | 94,649 | 2.6 | -32.8% |
| Mar 13, 2026 | 140,773 | 2.7 | -48.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Director / officer change · Regulation FD disclosureMay 28, 2026
- Results of operationsMay 15, 2026
- Results of operationsMar 31, 2026
- Entered a material agreement · Unregistered equity sale · Director / officer changeFeb 27, 2026
- Entered a material agreement · Unregistered equity saleFeb 13, 2026
- Entered a material agreement · Unregistered equity saleJan 9, 2026
- Entered a material agreement · Results of operations · Unregistered equity saleNov 14, 2025
- Entered a material agreement · Unregistered equity saleNov 6, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 4OWNERSHIP DOCUMENTMay 29, 2026
- 4OWNERSHIP DOCUMENTMay 29, 2026
- 4OWNERSHIP DOCUMENTMay 29, 2026
- 4OWNERSHIP DOCUMENTMay 29, 2026
- 4OWNERSHIP DOCUMENTMay 29, 2026
- 8-KFORM 8-KMay 28, 2026
- S-8FORM S-8May 21, 2026
- S-1May 21, 2026
- 4OWNERSHIP DOCUMENTMay 20, 2026
- 4OWNERSHIP DOCUMENTMay 20, 2026
- 4OWNERSHIP DOCUMENTMay 20, 2026
- 4OWNERSHIP DOCUMENTMay 20, 2026
- 4OWNERSHIP DOCUMENTMay 20, 2026
- 4OWNERSHIP DOCUMENTMay 20, 2026
- 8-KFORM 8-KMay 15, 2026
Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.